We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Saliva Testing for COVID-19 Quicker, Safer than Nasal Swabs

By LabMedica International staff writers
Posted on 23 Mar 2022
Print article
Image: New research supports use of saliva in large-scale screening (Photo courtesy of Pexels)
Image: New research supports use of saliva in large-scale screening (Photo courtesy of Pexels)

Early in the COVID-19 pandemic, the urgent need to increase testing was accompanied by a shortage of supplies, notably nasal swabs, which were then the standard method for collecting samples for testing. Research conducted in order to come up with a solution to this problem has now found that genetic testing of saliva samples identifies the SARS-CoV-2 virus more quickly than testing of nasal swabs.

To identify people with COVID-19, investigators at the University of Maryland (College Park, MD, USA) began conducting weekly tests of saliva samples from healthy community volunteers in May 2020 and continued over the next two years. Of the asymptomatic volunteers who tested positive, the researchers found that those patients would typically show symptoms a day or two later, making them wonder if saliva was better at catching pre-symptomatic patients than traditional nasal swabs.

To answer that question, the researchers used data from a companion study of close contacts of people with confirmed cases of COVID-19. In the study, the team collected saliva and mid-turbinate nasal swab samples from contacts every two or three days during their quarantine period. All the samples were tested using real-time reverse transcription polymerase chain reaction (RT-PCR) to detect SARS-CoV-2 and measure how much viral RNA was in the samples. The researchers then analyzed how these results changed in the days before and after symptom onset. The findings revealed that early in the course of infection, saliva was significantly more sensitive than mid-turbinate nasal swabs, notably so before the onset of symptoms. The study also noted that previous studies had shown that pre-symptomatic transmission plays a greater role than symptomatic transmission of SARS-CoV-2.

These findings have implications for improving public acceptance of COVID-19 testing, reducing the cost of mass COVID-19 screening and improving the safety of healthcare workers who conduct testing. In the latter case, saliva self-testing avoids the close contact between patient and healthcare worker that nasal swabbing entails and avoids causing patients to cough and sneeze, thereby spreading virus particles as a result of swabbing the sensitive nasal passages, as well as discomfort to patients.

“Our research supports the use of saliva in large-scale screening in schools and workplaces, as a means of improving screening rates, as well as early detection,” said coauthor Donald K. Milton, M.D., DrPH, a professor of occupational and environmental health at the Institute for Applied Environmental Health, University of Maryland School of Public Health, College Park. “We expect that if rapid saliva tests become available, they could be a major advance from the current nasal swab-based rapid tests.”

Related Links:
University of Maryland 

Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.